FOXQ1 and hepatocellular carcinoma: The postoperative pathological tissues of 27 HCC patients treated with sorafenib were collected, then the relationship between FOXQ1 immunohistochemical staining and the objective response rate of sorafenib treatment was analyzed, the results showed the expression of FOXQ1 in patients with sorafenib resistance was higher (Fig. 1E).